Dose-Dependent Effects of Ranolazine on Reentrant Ventricular Arrhythmias Induced After Subacute Myocardial Infarction in Rabbits

Moschovidis, V; Simopoulos, Vassilios; Stravela, Soultana; Δίπλα, Κωνσταντίνα; Hatziefthimiou, Apostolia; Stamatiou, Rodopi; Aidonidis, Isaac

doi:10.1177/1074248419858113

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this respect, it has been shown that the higher dose of ranolazine has antiarrhythmic effects, while the lower one seems to be ineffective or even proarrhythmic. The uthors supposed that the mechanism by which the ranolazine exerts its beneficial effects could be related to a significant increase in ventricular refractoriness possibly secondary to the IKr blockade [68].…”

Section: Arrhythmiasmentioning

confidence: 99%

Through the heart and beyond: a review on ranolazine

Uran¹

2021

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Ranolazine derives from piperazine and has been approved as a drug for the therapy of chronic stable angina. It acts by selectively inhibiting the late sodium inward current. Moreover, ranolazine has other metabolic features which makes it effective in other diseases as well as coronary artery ones. In this paper I make an updated review of all possible therapeutic roles of ranolazine: through cardiology and beyond.

show abstract

Section: Arrhythmiasmentioning

confidence: 99%

Through the heart and beyond: a review on ranolazine

Uran¹

2021

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

show abstract

Cardiovascular Effects of Ranolazine and the Scope for Translational Research: A Current Review of Literature

Fakıoğlu¹,

Yardım-Akaydin²

2022

Frontiers in Cardiovascular Drug Discovery

View full text Add to dashboard Cite

The decline in deaths from cardiovascular diseases in line with scientific developments between 1950-2010 was impressive. Despite these significant advances, cardiovascular (CV) diseases remain the leading cause of death worldwide. According to the World Health Organization (WHO) data, 17.9 million people die due to CV diseases every year, which corresponds to 31% of the total deaths worldwide. Therefore, for many CV diseases, there is still a need for improved treatment, and this is only possible with the development of new drugs. Although investments in the previous decade have resulted in the development of many innovative drugs in the treatment of CV diseases, today, pharmaceutical companies are less enthusiastic about developing CV drugs, mainly due to financial and regulatory difficulties. Indeed, today, institutes, associations and even organizations such as WHO are taking over the sponsorship role that pharmaceutical industry players have abandoned. In parallel, cardiovascular pipeline activity is shifting from large pharmaceutical companies to small and medium-sized companies and from fast following drugs to first-in classes. This transformation in CV drug discovery and development reveals significant challenges that require square up to. The aim of this chapter is to discuss the global challenges faced in CV drug discovery and development to find effective solutions.

show abstract

Spontaneously Resolved Ventricular Fibrillation and Ventricular Tachycardia in Arrhythmic Variant of Acute Myocardial Infarction (Clinical Case)

et al. 2019

View full text Add to dashboard Cite

Different heart rhythm disorders occur in almost all patients with myocardial infarction (MI). Arrhythmias in setting of MI are caused by electrical instability of myocardium as a result of metabolic and microcirculatory disorders. However, the presence of even severe heart rhythms disorders does not provide a basis for diagnosis of arrhythmic MI. In arrhythmic variant of infarction heart rhythm disorders and associated symptoms should prevail in clinical presentation. Supra ventricular or ventricular paroxysmal tachycardia, less often atrial fibrillation or flutter, and high degree AV block are registered most commonly. Pain may be absent or slight. Loss of consciousness is possible, due to cerebral blood circulation disorder. Arrhythmic variant may be accompanied by acute heart failure or significant arterial hypotension, up to arrhythmogenic shock. This variant of MI often occurs in older people who have anamnesis of structural heart diseases. In MI patients, reduction of cerebral blood circulation due to tachyarrhythmia and hypotension can cause ischemic stroke.

show abstract

Dose-Dependent Effects of Ranolazine on Reentrant Ventricular Arrhythmias Induced After Subacute Myocardial Infarction in Rabbits

Cited by 3 publications

References 21 publications

Through the heart and beyond: a review on ranolazine

Through the heart and beyond: a review on ranolazine

Cardiovascular Effects of Ranolazine and the Scope for Translational Research: A Current Review of Literature

Spontaneously Resolved Ventricular Fibrillation and Ventricular Tachycardia in Arrhythmic Variant of Acute Myocardial Infarction (Clinical Case)

Contact Info

Product

Resources

About